FamiCord is one of Europe’s leading providers in the field of stem cell storage. The company collects, processes and stores biological materials, in particular stem cells from umbilical cord blood and umbilical cord tissue. It also offers services for the development and manufacture of biopharmaceutical products. It is precisely this business, involving specialised development and production services, that is set to be further strengthened.
At the same time, FamiCord is working to simplify its group structure. Organisational changes are intended to make processes more efficient and reduce costs. Furthermore, the company is exploring opportunities to expand its activities into related business areas.
The financing is to be arranged through the issue of new shares, which will initially be offered to existing shareholders. The final terms have not yet been finalised.
Through these planned measures, FamiCord aims to combine the further development of its traditional stem cell business with the expansion of industrial services for the life sciences sector. It remains to be seen which additional business areas will play a greater role in future and how quickly the organisational changes will have an economic impact.
News from “FamiCord AG” dated 16 October 2026